Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

PEG-MGF cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established PEG-MGF cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • PEG-MGF combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established PEG-MGF cycle length?
No. We found no human studies that report a treatment duration for PEG-MGF.
What is the longest human study of PEG-MGF?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
PEG-MGF dosing reference Full research page

References

  1. Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping British Journal of Sports Medicine. 2005
  2. Detection of insulin analogues and large peptides >2 kDa in urine Drug Testing and Analysis. 2022
  3. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells American Journal of Physiology - Endocrinology and Metabolism. 2014
  4. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls Growth Hormone & IGF Research. 2014
  5. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H Drug Testing and Analysis. 2017
  6. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro In Vivo. 2009
  7. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Frontiers in Endocrinology. 2026
  8. Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells The Prostate. 2010
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  10. World Anti-Doping Code International Standard Prohibited List 2026 WADA. 2026
  11. PubMed search for PEG-MGF (one record) and ClinicalTrials.gov search for pegylated mechano growth factor (no registered studies) PubMed / ClinicalTrials.gov. 2026